Zentalis Pharmaceuticals IncNASDAQ:ZNTLNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE11.8800
- TODAY'S CHANGE (%)-0.0900 (-0.7519%)
- Bid / Lots10.8300/ 1
- Ask / Lots12.9100/ 1
- Open / Previous Close12.1900 / 11.9700
- Day Range
- 52 Week Range
- Volume838,191
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ZNTL |
|---|---|---|
| 09:32 ET | 3490 | 12.18 |
| 09:36 ET | 300 | 12.215 |
| 09:38 ET | 100 | 12.2565 |
| 09:39 ET | 15297 | 12.47 |
| 09:41 ET | 500 | 12.455 |
| 09:43 ET | 1777 | 12.755 |
| 09:45 ET | 400 | 12.7 |
| 09:48 ET | 22098 | 12.86 |
| 09:50 ET | 520 | 12.76 |
| 09:52 ET | 25285 | 12.71 |
| 09:54 ET | 100 | 12.74 |
| 09:56 ET | 1000 | 12.62 |
| 09:57 ET | 1182 | 12.555 |
| 09:59 ET | 200 | 12.58 |
| 10:01 ET | 300 | 12.59 |
| 10:03 ET | 500 | 12.59 |
| 10:06 ET | 2824 | 12.49 |
| 10:08 ET | 100 | 12.46 |
| 10:10 ET | 3470 | 12.55 |
| 10:12 ET | 400 | 12.58 |
| 10:14 ET | 2058 | 12.52 |
| 10:15 ET | 1565 | 12.585 |
| 10:17 ET | 977 | 12.605 |
| 10:19 ET | 401 | 12.6075 |
| 10:21 ET | 695 | 12.595 |
| 10:24 ET | 3400 | 12.58 |
| 10:26 ET | 4344 | 12.68 |
| 10:28 ET | 1354 | 12.7 |
| 10:30 ET | 508 | 12.685 |
| 10:32 ET | 500 | 12.685 |
| 10:33 ET | 2998 | 12.7 |
| 10:35 ET | 200 | 12.71 |
| 10:37 ET | 1557 | 12.6275 |
| 10:39 ET | 1030 | 12.64 |
| 10:42 ET | 649 | 12.61 |
| 10:44 ET | 100 | 12.58 |
| 10:46 ET | 300 | 12.5 |
| 10:48 ET | 300 | 12.47 |
| 10:50 ET | 2800 | 12.42 |
| 10:51 ET | 2722 | 12.4 |
| 10:53 ET | 8434 | 12.43 |
| 10:55 ET | 552 | 12.3 |
| 10:57 ET | 600 | 12.3 |
| 11:00 ET | 2041 | 12.31 |
| 11:02 ET | 4064 | 12.365 |
| 11:04 ET | 529 | 12.335 |
| 11:06 ET | 357 | 12.325 |
| 11:08 ET | 400 | 12.325 |
| 11:09 ET | 3400 | 12.34 |
| 11:11 ET | 100 | 12.34 |
| 11:13 ET | 100 | 12.335 |
| 11:15 ET | 900 | 12.3 |
| 11:18 ET | 304 | 12.305 |
| 11:20 ET | 708 | 12.255 |
| 11:24 ET | 100 | 12.26 |
| 11:26 ET | 300 | 12.245 |
| 11:27 ET | 200 | 12.25 |
| 11:29 ET | 900 | 12.23 |
| 11:31 ET | 300 | 12.25 |
| 11:33 ET | 300 | 12.25 |
| 11:36 ET | 1350 | 12.24 |
| 11:38 ET | 562 | 12.26 |
| 11:42 ET | 200 | 12.275 |
| 11:44 ET | 5770 | 12.21 |
| 11:49 ET | 300 | 12.2 |
| 11:51 ET | 500 | 12.185 |
| 11:56 ET | 200 | 12.19 |
| 11:58 ET | 600 | 12.21 |
| 12:00 ET | 600 | 12.16 |
| 12:02 ET | 683 | 12.15 |
| 12:03 ET | 200 | 12.155 |
| 12:05 ET | 214 | 12.16 |
| 12:07 ET | 1637 | 12.15 |
| 12:09 ET | 200 | 12.1 |
| 12:12 ET | 200 | 12.11 |
| 12:14 ET | 2591 | 12.09 |
| 12:18 ET | 2228 | 12.11 |
| 12:20 ET | 4104 | 12.055 |
| 12:21 ET | 200 | 12.05 |
| 12:23 ET | 790 | 12.0317 |
| 12:25 ET | 900 | 12.03 |
| 12:27 ET | 3648 | 12.045 |
| 12:30 ET | 1100 | 11.99 |
| 12:32 ET | 300 | 11.95 |
| 12:34 ET | 200 | 11.95 |
| 12:36 ET | 2880 | 11.955 |
| 12:39 ET | 300 | 11.93 |
| 12:41 ET | 200 | 11.93 |
| 12:43 ET | 400 | 11.92 |
| 12:45 ET | 2626 | 11.885 |
| 12:48 ET | 508 | 11.885 |
| 12:50 ET | 200 | 11.86 |
| 12:52 ET | 3432 | 11.97 |
| 12:54 ET | 3773 | 11.96 |
| 12:57 ET | 200 | 11.95 |
| 12:59 ET | 3708 | 11.92 |
| 01:01 ET | 848 | 11.99 |
| 01:03 ET | 300 | 12 |
| 01:06 ET | 357 | 11.97 |
| 01:08 ET | 300 | 11.96 |
| 01:10 ET | 992 | 11.97 |
| 01:12 ET | 200 | 11.96 |
| 01:14 ET | 390 | 11.96 |
| 01:15 ET | 777 | 11.98 |
| 01:17 ET | 1164 | 11.95 |
| 01:19 ET | 100 | 11.96 |
| 01:21 ET | 1169 | 11.98 |
| 01:24 ET | 1068 | 12 |
| 01:26 ET | 100 | 12.01 |
| 01:28 ET | 800 | 12.07 |
| 01:30 ET | 300 | 12.065 |
| 01:32 ET | 1900 | 12.01 |
| 01:33 ET | 179 | 11.99 |
| 01:35 ET | 205 | 11.98 |
| 01:37 ET | 600 | 11.97 |
| 01:39 ET | 811 | 11.97 |
| 01:42 ET | 300 | 11.96 |
| 01:44 ET | 1357 | 11.95 |
| 01:46 ET | 2968 | 11.99 |
| 01:48 ET | 179 | 11.97 |
| 01:50 ET | 600 | 12.01 |
| 01:51 ET | 161 | 11.99 |
| 01:53 ET | 980 | 11.97 |
| 01:55 ET | 546 | 11.98 |
| 01:57 ET | 100 | 11.96 |
| 02:00 ET | 969 | 11.975 |
| 02:02 ET | 157 | 11.96 |
| 02:04 ET | 100 | 11.95 |
| 02:06 ET | 390 | 11.95 |
| 02:08 ET | 1433 | 11.985 |
| 02:09 ET | 696 | 12.02 |
| 02:11 ET | 1900 | 12 |
| 02:13 ET | 1000 | 12.01 |
| 02:15 ET | 1999 | 11.98 |
| 02:18 ET | 200 | 11.98 |
| 02:20 ET | 200 | 11.99 |
| 02:22 ET | 200 | 12 |
| 02:24 ET | 904 | 12.03 |
| 02:26 ET | 2408 | 12.03 |
| 02:27 ET | 496 | 12.02 |
| 02:31 ET | 2317 | 11.95 |
| 02:33 ET | 300 | 11.95 |
| 02:36 ET | 100 | 11.945 |
| 02:38 ET | 1260 | 11.93 |
| 02:40 ET | 100 | 11.93 |
| 02:42 ET | 200 | 11.93 |
| 02:44 ET | 1012 | 11.95 |
| 02:45 ET | 247 | 11.935 |
| 02:47 ET | 200 | 11.92 |
| 02:49 ET | 600 | 11.94 |
| 02:51 ET | 700 | 11.91 |
| 02:54 ET | 200 | 11.9 |
| 02:56 ET | 879 | 11.92 |
| 02:58 ET | 400 | 11.93 |
| 03:00 ET | 100 | 11.94 |
| 03:02 ET | 1907 | 11.92 |
| 03:03 ET | 600 | 11.89 |
| 03:05 ET | 819 | 11.83 |
| 03:07 ET | 300 | 11.83 |
| 03:09 ET | 1300 | 11.86 |
| 03:12 ET | 610 | 11.85 |
| 03:14 ET | 1321 | 11.86 |
| 03:16 ET | 100 | 11.85 |
| 03:18 ET | 178 | 11.85 |
| 03:20 ET | 200 | 11.86 |
| 03:21 ET | 2900 | 11.82 |
| 03:23 ET | 2726 | 11.885 |
| 03:25 ET | 200 | 11.9 |
| 03:27 ET | 812 | 11.9 |
| 03:30 ET | 1500 | 11.865 |
| 03:32 ET | 1226 | 11.84 |
| 03:34 ET | 715 | 11.86 |
| 03:36 ET | 771 | 11.86 |
| 03:38 ET | 900 | 11.875 |
| 03:39 ET | 1017 | 11.9 |
| 03:41 ET | 900 | 11.91 |
| 03:43 ET | 2600 | 11.92 |
| 03:45 ET | 3633 | 11.94 |
| 03:48 ET | 7295 | 11.865 |
| 03:50 ET | 1510 | 11.84 |
| 03:52 ET | 11673 | 11.915 |
| 03:54 ET | 8356 | 11.93 |
| 03:56 ET | 4071 | 11.92 |
| 03:57 ET | 16175 | 11.91 |
| 03:59 ET | 214358 | 11.88 |
May 30, 2024
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference, from 7:00AM ET on Thursday May 30, 2024 by Dow Jones
7:00AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow JonesPress Release: Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors, from 7:00AM ET on Wednesday May 29, 2024 by Dow Jones
7:00AM ET on Wednesday May 29, 2024 by Dow Jones
May 23, 2024
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting, from 5:01PM ET on Thursday May 23, 2024 by Dow Jones
5:01PM ET on Thursday May 23, 2024 by Dow Jones
May 16, 2024
Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm, from 10:36AM ET on Thursday May 16, 2024 by Dow Jones
10:36AM ET on Thursday May 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Zentalis Pharmaceuticals Inc | 843.6M | -3.5x | --- |
Disc Medicine Inc | 839.3M | -10.1x | --- |
Tyra Biosciences Inc | 852.2M | -9.6x | --- |
ARS Pharmaceuticals Inc | 860.4M | -17.1x | --- |
ProKidney Corp | 806.3M | -6.1x | --- |
Perspective Therapeutics Inc | 881.0M | -8.5x | --- |
Company Information
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
Contact Information
- Headquarters
- 1359 Broadway, Suite 801NEW YORK, NY, United States 10018
- Phone
- 212-433-3791
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Johnson
- President, Executive Director
- Cam Gallagher
- Chief Executive Officer, Director
- Kimberly Blackwell
- Chief Financial Officer, Treasurer
- Melissa Epperly
- Chief Operating Officer
- Iris Roth
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $843.6M |
|---|---|
Revenue (TTM) | $40.6M |
Shares Outstanding | 71.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.83 |
EPS | $-3.36 |
Book Value | $6.18 |
P/E Ratio | -3.5x |
Price/Sales (TTM) | 20.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -639.35% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
